[1]Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Int Care Med,2010, 36(10): 1695-1702.
[2]Scott RB, Robb-Smith AH. Histiocytic medullary reticulocytosis. Lancet, 1939, 2: 194-983.
[3]Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child, 1952, 27: 519-525.
[4]Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer, 1979, 44(3): 993-1002.
[5]Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL study group of the histiocyte society. Sem Oncol, 1991, 18(1): 29-33.
[6]Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet, 2014, 383(9927): 1503-1516.
[7]Yoon JH, Park SS, Jeon YW, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. Haematologica, 2019, 104(2): 269-276.
[8]Henter JI, Horne A, Aricó M, et al. Hlh-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediat Blood Cancer, 2007, 48(2): 124-131.
[9]噬血细胞综合征中国专家联盟,中华医学会儿科学分会血液学组.噬血细胞综合征诊治中国专家共识.中华医学杂志,2018,98(2):91-95.
[10] zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (fhl-5) is caused by mutations in munc18-2 and impaired binding to syntaxin 11. Am J Human Genet, 2009, 85(4): 482-492.
[11] Hayden A, Park S, Giustini D, et al. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev, 2016, 30(6): 411-420.
[12] Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv, 2017, 1(26): 2529-2534.
[13] Naymagon L, Tremblay D. Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. Eur J Haematol,2020, 105(3): 255-261.
[14] Valade S, Mariotte E, Azoulay E. Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Crit Care Clin, 2020, 36(2): 415-426.
[15] Knaak C, Nyvlt P, Schuster FS, et al. Hemophagocytic lymphohistiocytosis in critically ill patients: Diagnostic reliability of HLH-2004 criteria and HScore. Crit Care, 2020, 24(1): 244.
[16] Bilston L, Croden J, Taparia M, et al. Validation of the HScore and the HLH-2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort. Eur J Haematol, 2022[ahead of print].
[17] Valade S, Monseau G, Mariotte E, et al. Diagnostic performance of hemophagocytic lymphohistiocytosis criteria and hscore in critically ill patients with severe hemophagocytic syndrome. Crit Care Med, 2021, 49(9): e874-e879.
[18] Smits BM, van Montfrans J, Merrill SA, et al. A minimal parameter set facilitating early decision-making in the diagnosis of hemophagocytic lymphohistiocytosis. J Clin Immunol, 2021, 41(6): 1219-1228.
[19] Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leukemia Lmphoma, 2000, 38(1-2): 121-130.
[20] Takahashi N, Chubachi A, Miura I, et al. Lymphoma-associated hemophagocytic syndrome in Japan. Jap J Clin Hematol, 1999, 40(7): 542-549.
[21] Shi J, Chu C, Yu M, et al. Clinical warning of hemophagocytic syndrome caused by epstein-barr virus. Ital J Pediat, 2021, 47(1): 3.
[22] Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediat Blood Cancer, 2019, 66(11): e27929.
[23] Shimizu M, Mizuta M, Yasumi T, et al. Validation of classification criteria of macrophage activation syndrome in japanese patients with systemic juvenile idiopathic arthritis. Arth Care Res, 2018, 70(9): 1412-1415. |
